Tag

oral cancer drug Archives - Walton Marketing

LightOx win £1.1 million Biomedical Catalyst grant to develop oral cancer drug

By | Client PR Stories | No Comments

Newcastle based LightOx announces today that it has been awarded a £1.1m project grant from Innovate UK, for the development of its light activated drug LXD191 to treat oral cancer patients. LightOx will work with the clinical team at the Liverpool Head and Neck Centre, University of Liverpool – Molecular and Clinical Cancer Medicine, and Liverpool University Hospitals NHS Foundation Trust. Working with the Liverpool team LightOx will finalise the drug formulation and clinical trial plans in order to then bring the drug to patients. The company was awarded the grant to formulate and manufacture their leading drug compound LXD191 to be used to treat oral cancer patients and pre-cancerous lesions that are detected in clinic. The LightOx team will work closely with partners to deliver a “chair-side” treatment for patients suffering from early-stage cancers. The drug which is currently the first of its kind to be developed for oral cancer is applied topically to the cancerous cells and is activated using a specific light source to kill the cancerous cells in the mouth. The treatment provides a minimally invasive alternative to surgery which currently remains the only other available option for patients, and often results in a reduced quality…

Read More